General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Andreessen Horowitz in Connection with Nautilus Biotechnology’s Proposed Merger with Arya Sciences Acquisition Corp III

February 22, 2021
A corporate team advises the investor in the US$200 million PIPE as part of the SPAC transaction.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III (Nasdaq: ARYA), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, have announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Arya III will redomicile as a Delaware corporation, be renamed Nautilus Biotechnology, Inc. and its common stock is expected to be listed on Nasdaq under the ticker symbol NAUT. In connection to the transaction, a group of premier healthcare investors has committed to invest in a US$200 million common stock PIPE. Investors in the PIPE include lead investor Perceptive Advisors, an affiliate of Arya III’s sponsor, as well as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., Casdin Capital and existing Nautilus Biotechnology shareholders including Andreessen Horowitz, Madrona Venture Group, and Vulcan Capital.

Latham & Watkins LLP represents Andreessen Horowitz in the transaction with a corporate team led by partners Justin Hamill, Ryan Maierson, and Benjamin Potter.